Novo is the single largest stock in the Stoxx Europe 600 index, with a weighting of more than 3%. Its fall weighed on the overall index, which is also contending with a Trump tariff threat against ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY). To watch more expert ...

The trial achieved its primary endpoint by "demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo." While the results showed promise, the market ...

The Grinch left his cave and stole most of the share value of Percheron Therapeutics (ASX:PER) on Wednesday after the company announced a poor trial result. The share price of Percheron fell ...

Shares in Novo Nordisk plunged 20% on Friday. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and ...

Galectin Therapeutics’ stock has halved since the company revealed ... Galectin tested the candidate out in a late-stage trial, dubbed NAVIGATE, that enrolled 355 patients with metabolic ...

Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data ... that it will break free from the selling pressure.

Avignon arrivals ahead of verdicts in the historic Gisèle Pelicot rape trial Gisele Pelicot speaks to the press as she leaves the courtroom, in the Avignon courthouse, southern France, Thursday, Dec.